Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 3006337 in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel (Sequential) Group Design)
Latest Information Update: 16 Mar 2023
At a glance
- Drugs BI 3006337 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 13 Mar 2023 Status changed from active, no longer recruiting to completed.
- 07 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 28 Dec 2022 Planned number of patients changed from 68 to 80.